Effective local delivery of bone anabolic agent to accelerate the healing of delayed fracture union
有效局部输送骨合成代谢剂加速骨折延迟愈合
基本信息
- 批准号:10565241
- 负责人:
- 金额:$ 45.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-20 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAffectAftercareAgingAlcohol consumptionAmericanAnabolic AgentsAnimal ModelAnticoagulantsAntiinflammatory EffectAutoimmune DiseasesAutologousBiodistributionBiologyBiomechanicsBlood VesselsBlood flowBone InjuryBone TransplantationBone callusCOVID-19 patientCellsCharacteristicsChronicClinicalClinical ManagementContrast MediaDevelopmentDiabetes MellitusDiseaseDoseDrug KineticsEstrogen deficiencyEuthanasiaEventExhibitsExposure toFDA approvedFemoral FracturesFemurFlow CytometryFormulationFractureGlucocorticoidsGoalsHospitalizationHydrogelsImmunofluorescence ImmunologicImpaired healingImpairmentIn VitroInflammatoryInvestmentsLabelLasersMicrofilsMolecularMolecular WeightMonitorMusOperative Surgical ProceduresOrthopedic SurgeryOrthopedicsOsteogenesisOsteoporosisPathologicPerfusionPharmaceutical PreparationsPharmacologyPharmacology StudyPhase TransitionPolymersPopulationPostmenopausePrednisonePreparationProceduresProcessProdrugsPropertyQuality of lifeRegimenResearchResolutionRisk FactorsSafetySalvia miltiorrhizaSamplingSiteSkeletonTemperatureTestingTherapeutic AgentsTherapeutic InterventionTimeTissuesTobaccoTobacco useTransition TemperatureTreatment EfficacyViscosityWaterWeightX-Ray Medical Imagingangiogenesisaqueousbonebone fracture repairbone qualitycandidate selectionchronic painclinical efficacyclinical translationcoronavirus diseasecurrent pandemicdensitydesigndrug release kineticseffective therapyfracture riskfunctional disabilityhealingimprovedin vivoin vivo optical imaginginfection rateinfection riskinsightlipophilicityliquid chromatography mass spectrometrymethacrylamidemicroCTmouse modelmusculoskeletal injurynovelosteogenicpost-pandemicpreclinical studyside effectstandard carewater solubility
项目摘要
ABSTRACT
Fracture is the leading musculoskeletal injury affecting over 9.4 million Americans annually. Approximately
~10% of fractures are complicated by delayed healing or non-union, resulting chronic pain, impaired mobility and
poor quality of life. Pathophysiological and habitual risk factors, including fracture site instability, concurrent
diseases (e.g., diabetes), chronic exposure to certain medications (e.g., glucocorticoids or GCs) and
tobacco/alcohol use are also major contributing causes, which may interfere with the fracture healing biology
and lead to delayed healing or non-union. GCs are widely used in treating hospitalized COVID patients. Given
the scale of the current pandemic and the significant COVID infection rate among the US population, a post
pandemic surge of fracture risk and delayed fracture healing cases may be anticipated. Currently, orthopaedic
surgery and autologous bone grafts are still the gold standard in clinical management of delayed fracture healing.
There are few FDA approved non-invasive therapeutic interventions for the treatment of GC-induced delayed
fracture healing. To address this significant unmet clinical need, we have developed a N-(2-
hydroxypropyl)methacrylamide (HPMA)-based water-soluble thermoresponsive polymeric prodrug (P-TAN) of
Tanshinone IIA (TAN, a potent bone anabolic agent). The aqueous solution of P-TAN is free-flowing at room
temperature and transitions into a hydrogel (ProGel-TAN) at ≥ 27°C, which provide a unique mechanism for
sustained local delivery of TAN. When tested in a prednisone-induced delayed fracture healing mouse model,
two consecutive monthly ProGel-TAN treatments were found to accelerate the fracture healing by 5 weeks
without any side effects observed. The biomechanical properties of the bone were also fully restored. While
two monthly ProGel-TAN treatment seems to be very promising, the current orthopaedic practice favors a single
dose treatment at the time of the fracture stabilization procedure for pragmatic reasons as well as less infection
risk. Therefore, we hypothesize that with further structural and formulation optimization, we will be able to identify
an optimized single dose ProGel-TAN formulation that is highly effective and safe in treating the GC-induced
delayed fracture union. To test this hypothesis, we propose three Specific Aims in this project: 1. To characterize
the impact of different structural and formulation parameters of ProGel-TAN; 2. To identify single dose ProGel-
TAN formulations that provide optimal fracture healing efficacy; 3. To understand ProGel-TAN’s unique
pharmacology and putative mechanisms of action. At the successful completion of the proposed research, we
anticipate the identification of at least one optimal ProGel-TAN formulation that would satisfy the demand for a
single dose treatment to accelerate the healing of the GC-induced delayed fracture union by ~ 5 weeks and
normalize biomechanical properties of the injured bone in mice. It will then be subjected to further pre-clinical
studies on large animal models in preparation for clinical translation.
摘要
骨折是主要的肌肉骨骼损伤,每年影响超过940万美国人。约
约10%的骨折并发延迟愈合或骨不连,导致慢性疼痛,活动能力受损,
生活质量差。病理生理和习惯性风险因素,包括骨折部位不稳定,并发症
疾病(例如,糖尿病),长期暴露于某些药物(例如,糖皮质激素或GC)和
吸烟/饮酒也是主要的原因,这可能会干扰骨折愈合生物学
并导致延迟愈合或不愈合。GC广泛用于治疗住院的COVID患者。给定
当前疫情的规模和美国人口中的COVID感染率,
骨折风险和延迟骨折愈合病例的流行性激增是可以预期的。目前,骨科
手术和自体骨移植仍然是临床治疗骨折延迟愈合的金标准。
FDA批准的非侵入性治疗干预用于治疗GC诱导的迟发性
骨折愈合为了解决这一重大的未满足的临床需求,我们开发了一种N-(2-
羟丙基)甲基丙烯酰胺(HPMA)基水溶性温敏性聚合物前药(P-TAN)
丹参酮Ⅱ A(TAN,a potent bone anabolic agent). P-TAN的水溶液在室温下是自由流动的。
在≥ 27°C温度下转变为水凝胶(ProGel-TAN),这为生物降解提供了独特的机制。
持续的TAN局部递送。当在泼尼松诱导的骨折延迟愈合小鼠模型中进行测试时,
连续两个月的ProGel-TAN治疗被发现可以加速骨折愈合5周
没有观察到任何副作用。骨的生物力学性能也得到了完全恢复。而
两个月的ProGel-TAN治疗似乎是非常有希望的,目前的骨科实践倾向于单一的
在骨折稳定手术时进行剂量治疗,以减少感染
风险因此,我们假设,通过进一步的结构和配方优化,我们将能够识别
一种优化的单剂量ProGel-TAN制剂,在治疗GC诱导的
骨折延迟愈合。为了验证这一假设,我们提出了三个具体目标:1。表征
ProGel-TAN的不同结构和制剂参数的影响; 2.为了确定单剂量ProGel-
提供最佳骨折愈合功效的TAN制剂; 3.了解ProGel-TAN独特的
药理学和假定的作用机制。在成功完成拟议的研究后,我们
预期鉴定至少一种最佳的ProGel-TAN制剂,其将满足对
单次给药治疗可加速GC诱导的延迟骨折愈合约5周,
使小鼠受损骨骼的生物力学特性正常化。然后将其进行进一步的临床前
为临床转化做准备的大型动物模型研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dong Wang其他文献
Dong Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dong Wang', 18)}}的其他基金
Recognition of Synthetic Unnatural Base Pairs by RNA Polymerase
RNA 聚合酶对合成非天然碱基对的识别
- 批准号:
10561543 - 财政年份:2023
- 资助金额:
$ 45.3万 - 项目类别:
Towards Precision Nutrition for Alzheimer's Dementia Prevention: A Prospective Study of Dietary Patterns, the Gut Microbiome and Cognitive Function
预防阿尔茨海默病的精准营养:饮食模式、肠道微生物组和认知功能的前瞻性研究
- 批准号:
10447872 - 财政年份:2022
- 资助金额:
$ 45.3万 - 项目类别:
Towards Precision Nutrition for Alzheimer's Dementia Prevention: A Prospective Study of Dietary Patterns, the Gut Microbiome and Cognitive Function
预防阿尔茨海默病的精准营养:饮食模式、肠道微生物组和认知功能的前瞻性研究
- 批准号:
10629237 - 财政年份:2022
- 资助金额:
$ 45.3万 - 项目类别:
Nonaddictive opioid prodrug nanomedicine for musculoskeletal pain
用于治疗肌肉骨骼疼痛的非成瘾性阿片类药物前体纳米药物
- 批准号:
10700168 - 财政年份:2022
- 资助金额:
$ 45.3万 - 项目类别:
Molecular Mechanisms for DNA Damage Processing by Transcription Machinery
转录机器处理 DNA 损伤的分子机制
- 批准号:
10435882 - 财政年份:2021
- 资助金额:
$ 45.3万 - 项目类别:
The Gut Microbiome and Personalized Mediterranean Diet Interventions for Cardiometabolic Disease Prevention
用于预防心血管代谢疾病的肠道微生物组和个性化地中海饮食干预措施
- 批准号:
10275622 - 财政年份:2021
- 资助金额:
$ 45.3万 - 项目类别:
The Gut Microbiome and Personalized Mediterranean Diet Interventions for Cardiometabolic Disease Prevention
用于预防心血管代谢疾病的肠道微生物组和个性化地中海饮食干预措施
- 批准号:
10493258 - 财政年份:2021
- 资助金额:
$ 45.3万 - 项目类别:
The Gut Microbiome and Personalized Mediterranean Diet Interventions for Cardiometabolic Disease Prevention
用于预防心血管代谢疾病的肠道微生物组和个性化地中海饮食干预措施
- 批准号:
10653220 - 财政年份:2021
- 资助金额:
$ 45.3万 - 项目类别:
Mediterranean Diet, Polyphenol-Rich Foods, Gut Microbiota and Type 2 Diabetes
地中海饮食、富含多酚的食物、肠道微生物群和 2 型糖尿病
- 批准号:
10457834 - 财政年份:2020
- 资助金额:
$ 45.3万 - 项目类别:
Mediterranean Diet, Polyphenol-Rich Foods, Gut Microbiota and Type 2 Diabetes
地中海饮食、富含多酚的食物、肠道微生物群和 2 型糖尿病
- 批准号:
10178327 - 财政年份:2020
- 资助金额:
$ 45.3万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 45.3万 - 项目类别:
Research Grant